Medindia

X

Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C

Monday, November 23, 2009 General News J E 4
Advertisement
- Data Monitoring Committee (DMC) determines RG7128, a first-in-class nucleoside analog polymerase inhibitor continues to have acceptable safety profile

Contact

Richard E. T. Smith, Ph.D.

VP, Investor Relations and Corporate Communications

richard.smith@pharmasset.com

Office: +1 (609) 613-4181

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Raptor Pharmaceutical Completes DR Cysteamine Phas...
S
Immune Design Corp. Announces Appointment of Dr. B...